Fact based stock research
Nabriva Therapeutics (NasdaqGS:NBRV)


Nabriva Therapeutics stock research in summary

nabriva.com


Nabriva Therapeutics shares are more expensive than other comparable stocks. While they are safely financed, they are poor value, and show below average growth. We recommend evaluating whether the future of the company Nabriva Therapeutics is really as positive as the high price of the shares suggests. If you come to the conclusion that the future for this company is only average, that could be a reason to sell this share.


Latest Obermatt Ranks


Country Austria
Industry Pharmaceuticals
Index NASDAQ
Size class X-Small

August 2, 2019. Stock data may be delayed. Login to get the most recent research.


Research History: Nabriva Therapeutics

RESEARCH HISTORY 2016 2017 2018 2019
VALUE
VALUE
GROWTH
GROWTH
SAFETY
SAFETY
COMBINED
COMBINED

Last update of Combined Rank: 2-Aug-2019. Financial reporting date used for calculating ranks: 31-Mar-2019. Stock research history is based on the Obermatt Method. The higher the rank, the better Nabriva Therapeutics is in the corresponding investment strategy.


Value Metrics in Detail

VALUE METRICS 2016 2017 2018 2019
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S)
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E)
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book)
DIVIDEND YIELD
DIVIDEND YIELD
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE

Last update of Value Rank: 2-Aug-2019. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Nabriva Therapeutics; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2016 2017 2018 2019
REVENUE GROWTH
REVENUE GROWTH
PROFIT GROWTH
PROFIT GROWTH
STOCK RETURNS
STOCK RETURNS
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH

Last update of Growth Rank: 31-Mar-2019. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Nabriva Therapeutics.


Safety Metrics in Detail

SAFETY METRICS 2016 2017 2018 2019
LEVERAGE
LEVERAGE
REFINANCING
REFINANCING
LIQUIDITY
LIQUIDITY
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY

Last update of Safety Rank: 26-Jul-2019. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Nabriva Therapeutics and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Nabriva Therapeutics from August 2, 2019.


We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.

Register for
stock tips now


Stock investing made easy